Brave Innovations: Public and Private Solutions to Advance Alzheimer’s Therapeutics and Diagnostic in a Risk-Averse Climate

12:00 PM - 12:55 PM, Monday, June 8, 2020 ・ Track Atlantic (originally)
Search General Info
Search Education
Search Partnering Companies
Alzheimer’s disease (AD) and AD-related dementias (ADRD) affect more than 5 million Americans and are expected to impact 13.8 million people by 2050. These diseases devastate families globally, while costing the U.S. health care system over $1 trillion. Despite a risk-averse environment due to clinical trial failures, significant investments and innovations that extend beyond traditional research paradigms to effectively treat and prevent AD/ADRD are needed. No disease-modifying treatments currently exist to treat AD/ADRD, and there is a lack of low-cost, blood-based diagnostic tools for early detection of AD/ADRD. This session will explore new opportunities for the biotech community, including seed funding through the NIH SBIR/STTR programs, that can spark innovation in AD/ADRD research. Panelists will share how entrepreneurs and researchers in the AD/ADRD space can access and leverage available support. Panelists will discuss how the launch of a new public-private partnership between ADDF and NIH will accelerate the development of novel innovations.
Chief, Office of Small Business Research
C2N Diagnostics
Co-Founder and CSO
Cognition Therapeutics
Head, Johnson & Johnson Innovation, East North America
Johnson & Johnson Innovation
Scientific Program Officer
Alzheimer’s Disease Discovery Foundation (ADDF)